Cite
HARVARD Citation
Kim, D. et al. (2022). BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British journal of haematology. pp. 136-145. [Online].